Skip to main content
SpringerPlus

Table 3 The risk of developing additional cancer due to occupational exposure to CP

From: Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital

First test (before PhaSeal®)

Second test (after PhaSeal®)

Pharmacist

CP (ng/24 h)

Cancer risk *

Pharmacist

CP (ng/24 h)

Cancer risk *

1

34.9

0.27 -1.94

1

nd

-

2

27.0

0.21 -1.50

2

nd

-

3

56.5

0.44 - 3.14

3

6.4

0.05-0.36

4

71.3

0.55 -3.96

4

7.8

0.06-0.43

  1. nd: not detected.
  2. The first test was conducted on September 12, 2007.
  3. The second test was conducted on March 18, 2009.
  4. *Cancer risk: extra cancer cases in a million workers each year.
Back to article page